Literature DB >> 9767654

7-Arylidenenaltrexones as selective delta1 opioid receptor antagonists.

S Ohkawa1, P S Portoghese.   

Abstract

A series of 7-arylidinenaltrexones (2a-m) related to the prototypical delta1-selective antagonist, 7-benzylidenenaltrexone 1 (BNTX), have been synthesized in an effort to develop more selective ligands. Testing in smooth muscle preparations revealed that members of the series exhibited varying degrees of selectively for delta receptors, with the o-methoxy (2e) and o-chloro (2j) congeners being most potent and most selective (Ke approximately 0.8 nm). Evaluation of 1, 2e, and 2f sc in mice using the tail-flick procedure indicated that they are selective delta1 opioid receptor antagonists in the lower dose range. At high doses these ligands, including BNTX, exhibited decreased delta1 selectivity due to increases in the ED50 ratios of [D-Ser2,Leu5]enkephalin-Thr6 and morphine. It is concluded that 2e and 2f possess in vivo selectivity similar to that of BNTX, but are less potent as delta1 antagonists.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9767654     DOI: 10.1021/jm980384s

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  2 in total

1.  Benzylideneoxymorphone: A new lead for development of bifunctional mu/delta opioid receptor ligands.

Authors:  Jason R Healy; Padmavani Bezawada; Nicholas W Griggs; Andrea L Devereaux; Rae R Matsumoto; John R Traynor; Andrew Coop; Christopher W Cunningham
Journal:  Bioorg Med Chem Lett       Date:  2016-11-22       Impact factor: 2.823

2.  Structure-Activity Relationship between Thiol Group-Trapping Ability of Morphinan Compounds with a Michael Acceptor and Anti-Plasmodium falciparum Activities.

Authors:  Noriki Kutsumura; Yasuaki Koyama; Tsuyoshi Saitoh; Naoshi Yamamoto; Yasuyuki Nagumo; Yoshiyuki Miyata; Rei Hokari; Aki Ishiyama; Masato Iwatsuki; Kazuhiko Otoguro; Satoshi Ōmura; Hiroshi Nagase
Journal:  Molecules       Date:  2020-03-02       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.